Kleinman Leah, Lowin Ana, Flood Emuella, Gandhi Gian, Edgell Eric, Revicki Dennis
MEDTAP International Inc, Bethesda, Maryland, USA.
Pharmacoeconomics. 2003;21(9):601-22. doi: 10.2165/00019053-200321090-00001.
Bipolar disorder is a chronic affective disorder that causes significant economic burden to patients, families and society. It has a lifetime prevalence of approximately 1.3%. Bipolar disorder is characterised by recurrent mania or hypomania and depressive episodes that cause impairments in functioning and health-related quality of life. Patients require acute and maintenance therapy delivered via inpatient and outpatient treatment. Patients with bipolar disorder often have contact with the social welfare and legal systems; bipolar disorder impairs occupational functioning and may lead to premature mortality through suicide. This review examines the symptomatology of bipolar disorder and identifies those features that make it difficult and costly to treat. Methods for assessing direct and indirect costs are reviewed. We report on comprehensive cost studies as well as administrative claims data and program evaluations. The majority of data is drawn from studies conducted in the US; however, we discuss European studies when appropriate. Only two comprehensive cost-of-illness studies on bipolar disorder, one prevalence-based and one incidence-based, have been reported. There are, however, several comprehensive cost-of-illness studies measuring economic burden of affective disorders including bipolar disorder. Estimates of total costs of affective disorders in the US range from $US30.4-43.7 billion (1990 values). In the prevalence-based cost-of-illness study on bipolar disorder, total annual costs were estimated at $US45.2 billion (1991 values). In the incidence-based study, lifetime costs were estimated at $US24 billion. Although there have been recent advances in pharmacotherapy and outpatient therapy, hospitalisation still accounts for a substantial portion of the direct costs. A variety of outpatient services are increasingly important for the care of patients with bipolar disorder and costs in this area continue to grow. Indirect costs due to morbidity and premature mortality comprise a large portion of the cost of illness. Lost workdays or inability to work due to the disease cause high morbidity costs. Intangible costs such as family burden and impaired health-related quality of life are common, although it has proved difficult to attach monetary values to these costs.
双相情感障碍是一种慢性情感障碍,给患者、家庭和社会带来巨大的经济负担。其终生患病率约为1.3%。双相情感障碍的特征是反复出现躁狂或轻躁狂以及抑郁发作,这些发作会导致功能受损和与健康相关的生活质量下降。患者需要通过住院和门诊治疗进行急性和维持治疗。双相情感障碍患者经常与社会福利和法律系统接触;双相情感障碍会损害职业功能,并可能通过自杀导致过早死亡。本综述研究了双相情感障碍的症状学,并确定了那些使其治疗困难且成本高昂的特征。还综述了评估直接和间接成本的方法。我们报告了全面的成本研究以及行政索赔数据和项目评估。大部分数据来自美国进行的研究;然而,我们会在适当的时候讨论欧洲的研究。关于双相情感障碍,仅报告了两项全面的疾病成本研究,一项基于患病率,一项基于发病率。然而,有几项全面的疾病成本研究衡量了包括双相情感障碍在内的情感障碍的经济负担。美国情感障碍的总成本估计在304亿至437亿美元之间(1990年价值)。在基于患病率的双相情感障碍疾病成本研究中,年度总成本估计为452亿美元(1991年价值)。在基于发病率的研究中,终生成本估计为240亿美元。尽管最近在药物治疗和门诊治疗方面取得了进展,但住院治疗仍占直接成本的很大一部分。各种门诊服务对双相情感障碍患者的护理越来越重要,这一领域的成本也在持续增长。由于发病和过早死亡导致的间接成本占疾病成本的很大一部分。因病导致的工作日损失或无法工作会产生高昂的发病成本。家庭负担和与健康相关的生活质量受损等无形成本很常见,尽管事实证明很难为这些成本赋予货币价值。